Key Highlights
NEW YORK, July 14, 2022 /PRNewswire/ -- Paradigm Biopharmaceuticals Ltd (ASX: PAR) (Paradigm or the Company) a clinical stage biopharmaceutical company focussed on repurposing existing molecules for new indications with unmet clinical needs, is pleased to announce it has entered into a corporate partnership with NFL Alumni Health (NFLAH). This partnership will inform NFL Alumni Association (NFLAA) members about osteoarthritis disease onset and progression, current treatment options, and provide information about actively enrolling clinical trials throughout the U.S.
Read more at prnewswire.com